Overzealous ordering of GDMT in ESRD pts (SGLT2i + spironolactone)
Our cardiology team orders these reflexively. I understand that much of the recommendation for SGLT2 inhibitors has been extrapolated from the earlier trials where dialysis patients were excluded from those studies.
I have not been able to find robust literature establishing a clear safety profile or meaningful clinical benefit specifically in the HD population. Same with spironolactone, I see it used frequently despite the obvious concerns regarding hyperkalemia. We had an anuric HD patient who was recently admitted for euglycemic DKA, and Jardiance was added per our cardiologists’s consult during previous admission.
Are there any cardiology pharmacists specialists who could provide better insight into how these medications are being justified and risk-stratified in HD patients?